Jade Biosciences reports Q2 2026 net loss of $55.8 million; cash $461 million
Jade Biosciences reported a second-quarter 2026 net loss of $55.8 million, up from $32.1 million a year earlier, as research and development and general and administrative expenses rose. The company said its $461.2 million in cash, cash equivalents and investments should fund operations into the fourth quarter of 2028, and it outlined pipeline timelines for JADE101, JADE201 and JADE301.
Key points
- Net loss was $55.8 million for the quarter ended June 30, 2026, compared with $32.1 million a year earlier.
- R&D expenses were $50.1 million, up from $22.5 million, and G&A expenses were $8.9 million, up from $5.2 million.
- Cash, cash equivalents and investments were $461.2 million as of June 30, 2026, versus $336.2 million at December 31, 2025.
- The company completed a $172.5 million public offering and expects its Phase 3 JADE101 trial to begin in the first half of 2027, pending FDA feedback.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.